Literature DB >> 16239769

Mirtazapine treatment for pathological laughing and crying after stroke.

Sung-Wan Kim1, Il-Seon Shin, Jae-Min Kim, So-Yeon Lim, Su-Jin Yang, Jin-Sang Yoon.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) have been recognized as the treatment of choice for pathological laughing and crying (PLC), which is a common, distressing condition that follows stroke. There have been few reports about other treatment options for PLC. Here, the authors report rapid responses to mirtazapine in two patients with poststroke PLC who failed to respond to SSRIs or bupropion. In the first case, a 63-year-old woman with severe long-standing crying spells that had persisted for 3 months responded well to low-dose mirtazapine within a few days; she could not tolerate citalopram or sertraline. In the second case, both the laughing and crying spells of a 64-year-old woman were improved within a few days of mirtazapine administration, after they had not responded to bupropion. This is one of the first reports to suggest that mirtazapine may be an alternative to SSRIs for treating poststroke PLC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239769     DOI: 10.1097/01.wnf.0000185825.34819.ba

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

1.  The recognition and management of psychological reactions to stroke: a case discussion.

Authors:  Lyvia S Chriki; Szofia S Bullain; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 2.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 3.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  [Amyotrophic lateral sclerosis: management of bulbar symptoms].

Authors:  P Kraft; M Beck; A Grimm; C Wessig; K Reiners; K V Toyka
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

5.  The causes and treatment of pseudobulbar affect in ischemic stroke.

Authors:  Preethi Balakrishnan; Howard Rosen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 6.  Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Authors:  Howard Rosen
Journal:  Drugs Today (Barc)       Date:  2008-09       Impact factor: 2.245

7.  Pharmaceutical interventions for emotionalism after stroke.

Authors:  Sabine Allida; Kulsum Patel; Allan House; Maree L Hackett
Journal:  Cochrane Database Syst Rev       Date:  2019-03-19

8.  Two cases of emotional disorder after middle cerebral artery infarction showing distinct responses to antidepressant treatment.

Authors:  Kengo Shimoda; Mahito Kimura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-23       Impact factor: 2.570

Review 9.  Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Authors:  Kerri A Schoedel; Sarah A Morrow; Edward M Sellers
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-26       Impact factor: 2.570

10.  Psychiatric comorbidity and quality of life in patients with post-stroke emotional incontinence.

Authors:  Dong-Ho Choi; Bo-Ok Jeong; Hee-Ju Kang; Sung-Wan Kim; Jae-Min Kim; Il-Seon Shin; Joon-Tae Kim; Man-Seok Park; Ki-Hyun Cho; Jin-Sang Yoon
Journal:  Psychiatry Investig       Date:  2013-10-16       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.